Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in
different ways. Some block the ability of cancer cells to grow and spread. Others find cancer
cells and help kill them or carry cell-killing substances to them. Drugs used in
chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth
of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide
may stop the growth of cancer by blocking blood flow to the tumor. Giving rituximab together
with bendamustine hydrochloride and lenalidomide may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving rituximab
together with bendamustine hydrochloride and lenalidomide in treating patients with
aggressive B-cell lymphoma.